OncoMatch/Clinical Trials/NCT06953999
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Is NCT06953999 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine for pancreatic cancer.
Treatment: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine — This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the addition of Ivonescimab and/or AK117 improves clinical outcomes compared to standard chemotherapy alone. Participants will be randomly assigned to receive either Ivonescimab with/without AK117 or placebo, both in combination with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Excluded: PALB2 germline mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-angiogenic therapy
Cannot have received: immunotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify